Affiliations 

  • 1 Saw Swee Hock School of Public Health, National University of Singapore (NUS), Singapore, Singapore
  • 2 Health Intervention and Technology Assessment Program (HITAP), Ministry of Health, Mueang Nonthaburi, Thailand
  • 3 National Institute for Health and Care Excellence (NICE), London, UK
  • 4 Ewha Womans University, Seoul, South Korea
  • 5 Sunnybrook Odette Cancer Centre, Toronto, Canada
  • 6 Essential Medicine and Technology Division, Department of Medical Services, Ministry of Health, Bhutan
  • 7 KK Women's and Children's Hospital, Singapore, Singapore
  • 8 Health Technology Assessment Unit, Department of Health, Manila, Philippines
  • 9 Faculty of Medicine, University of Adelaide, Adelaide, Australia
  • 10 China Health Technology Assessment Centre, National Health Development Research Centre, Ministry of Health, Beijing, China
  • 11 Hitotsubashi Institute for Advanced Study, Hitotsubashi University, Tokyo, Japan
  • 12 Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore
  • 13 School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India
  • 14 National Hepatitis C Program Office, Ministry of Health and Welfare, Taipei, Taiwan
  • 15 Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
  • 16 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia
  • 17 Center for Medical Technology Policy (CMTP), Baltimore, USA
  • 18 Cancer Research Program, School of Public Health and Preventive Medicine, Monash University, Clayton, Australia
Int J Technol Assess Health Care, 2020 Oct;36(5):474-480.
PMID: 32928330 DOI: 10.1017/S0266462320000628

Abstract

There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for health technology assessment (HTA). Optimal collection, analysis, and use of RWD/RWE to inform HTA requires a conceptual framework to standardize processes and ensure consistency. However, such framework is currently lacking in Asia, a region that is likely to benefit from RWD/RWE for at least two reasons. First, there is often limited Asian representation in clinical trials unless specifically conducted in Asian populations, and RWD may help to fill the evidence gap. Second, in a few Asian health systems, reimbursement decisions are not made at market entry; thus, allowing RWD/RWE to be collected to give more certainty about the effectiveness of technologies in the local setting and inform their appropriate use. Furthermore, an alignment of RWD/RWE policies across Asia would equip decision makers with context-relevant evidence, and improve timely patient access to new technologies. Using data collected from eleven health systems in Asia, this paper provides a review of the current landscape of RWD/RWE in Asia to inform HTA and explores a way forward to align policies within the region. This paper concludes with a proposal to establish an international collaboration among academics and HTA agencies in the region: the REAL World Data In ASia for HEalth Technology Assessment in Reimbursement (REALISE) working group, which seeks to develop a non-binding guidance document on the use of RWD/RWE to inform HTA for decision making in Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.